Pulmonary arterial hypertension (PAH) Clinical Trials EU — 14 Studies

Filter these 14 trials by phase, country, sponsor and more.

Open in Search →

SOFAPI Pending

2025-520731-17-02 5
Phase 2 Study of REGN13335 in Adult Participants with Pulmonary Arterial Hypertension (PAH) Recruiting

2024-514754-79-00 4 2026-05-06
A Long-term Follow-up Study of Sotatercept for PAH Treatment Recruiting

2023-509138-21-00 5 2021-08-26
Open-label, single-arm, non-controlled trial to evaluate the safety and tolerability of treprostinil sodium in children below the age of 18 … Recruiting

2023-505082-91-00 5 2024-05-29
A clinical study of sotatercept in people with pulmonary arterial hypertension (MK-7962-038) Recruitment ended

2025-521970-33-00 5 2025-12-19
A clinical study of sotatercept in people with pulmonary arterial hypertension Recruitment ended

2024-518687-12-00 4 2025-06-19
"Clinical Study of Inhaled GB002 for the Treatment of WHO Group 1 Pulmonary Arterial Hypertension (PAH)" Recruitment ended

2024-516754-22-00 4 2021-07-14
An open-label extension (OLE) study to evaluate the long-term safety and efficacy of ralinepag in patients with pulmonary arterial hypertens … Recruitment ended

2023-509305-68-00 5 2019-05-16
Riociguat for treatment of PAH in children from 6 to less than 18 years old Recruitment ended

2023-503536-40-00 5 2016-02-23
A clinical study of sotatercept in people with pulmonary arterial hypertension (MK-7962-024) Ended

2024-512278-92-00 4 2024-12-09
Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial – Follow Up Long Term Extension (IMPAHCT-FUL) Ended

2023-508735-31-00 5 2023-05-05
Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial (IMPAHCT) or A Phase 2b/3, Randomized, Controlled, 24-week Dose Ranging and … Ended

2023-508734-34-00 10 2022-06-30
A study to evaluate Sotatercept in Participants with PAH WHO FC III or FC IV at High Risk of Mortality Ended

2023-509140-10-00 5 2022-04-05
A study evaluating the efficacy and safety of ralinepag in treatment of patients with pulmonary arterial hypertension. Ended

2023-509304-16-00 5 2019-05-16

Showing 1–14 of 14 trials